menu
    • menu
    [{"orgOrder":0,"company":"Diurnal Group","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diurnal Group","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Diurnal Group \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"EffRx","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ EffRx","highestDevelopmentStatusID":"12","companyTruncated":"Diurnal Group \/ EffRx"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Hydrocortisone","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Diurnal Group \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Diurnal Group \/ Not Applicable"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Citrine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Diurnal Group","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ Citrine","highestDevelopmentStatusID":"12","companyTruncated":"Diurnal Group \/ Citrine"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Diurnal Group \/ Not Applicable"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Citrine Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Hydrocortisone","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ Citrine Medicine","highestDevelopmentStatusID":"12","companyTruncated":"Diurnal Group \/ Citrine Medicine"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Diurnal Group \/ Not Applicable"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Diurnal Group \/ Not Applicable"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"EffRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ Diurnal Group","highestDevelopmentStatusID":"12","companyTruncated":"Diurnal Group \/ Diurnal Group"}]

    Find Clinical Drug Pipeline Developments & Deals by Diurnal Group

    Menu

    Diurnal Group

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Diurnal Group

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Diurnal Group

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydrocortisone

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Recipient : EffRx Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            EffRx Pharmaceuticals Signs Exclusive License Agreement With Diurnal for the Registration and Commercializatio...

                            Details : Efmody® is a modified-release preparation of hydrocortisone that has been specifically designed for the treatment of patients with CAH, a rare condition caused by a genetic deficiency of adrenal enzymes.

                            Brand Name : Efmody

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 26, 2022

                            Lead Product(s) : Hydrocortisone

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Recipient : EffRx Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Diurnal Group

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Diurnal Group

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydrocortisone

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Diurnal Group launches Efmody in UK to Treat Patients with Rare Condition Congenital Adrenal Hyperplasia

                            Details : Efmody® is a preparation of hydrocortisone that has been specifically designed for patients with CAH, a rare condition caused by deficiency of adrenal enzymes, most commonly 21-hydroxylase.

                            Brand Name : Efmody

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 13, 2021

                            Lead Product(s) : Hydrocortisone

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Diurnal Group

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Diurnal Group

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydrocortisone

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : Citrine Medicine

                            Deal Size : $2.2 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Diurnal Triggers $1.25m in Milestone Payments from Citrine Medicine

                            Details : The $1.25 million milestone payment has been triggered as a result of the recent European Commission’s approval for Efmody® (hydrocortisone modified-release hard capsules) and the attainment by Citrine of certain development milestones in China for A...

                            Brand Name : Efmody

                            Molecule Type : Small molecule

                            Upfront Cash : $1.0 million

                            June 01, 2021

                            Lead Product(s) : Hydrocortisone

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : Citrine Medicine

                            Deal Size : $2.2 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Diurnal Group

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Diurnal Group

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydrocortisone

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Diurnal Group plc - Diurnal receives European Commission approval for Efmody®

                            Details : Efmody® is a preparation of hydrocortisone that has been specifically designed for patients with CAH, an orphan condition caused by deficiency of adrenal enzymes, most commonly 21-hydroxylase.

                            Brand Name : Efmody

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 28, 2021

                            Lead Product(s) : Hydrocortisone

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Diurnal Group

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Diurnal Group

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydrocortisone

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Diurnal Group plc - Chronocort® Phase 3 and Safety Extension Study Results Published in JCEM

                            Details : The Phase 3 study results published by the JCEM found that although the standard-deviation-score-focused primary endpoint of the study was missed, Chronocort® improved morning and early afternoon biochemical control for adults with CAH over standard glu...

                            Brand Name : Chronocort

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 02, 2021

                            Lead Product(s) : Hydrocortisone

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Diurnal Group

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Diurnal Group

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydrocortisone

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : Citrine

                            Deal Size : $13.2 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Citrine Medicine Announces Strategic Partnership with Diurnal To Bring Alkindi® To China For Use In Pediatric...

                            Details : Citrine will be responsible for obtaining registration for Alkindi® as a treatment for paediatric patients in China and for all commercialisation activities, including pricing and reimbursement.

                            Brand Name : Alkindi

                            Molecule Type : Small molecule

                            Upfront Cash : $0.5 million

                            January 27, 2021

                            Lead Product(s) : Hydrocortisone

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : Citrine

                            Deal Size : $13.2 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Diurnal Group

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Diurnal Group

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydrocortisone

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Eton Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI® SPRINKLE

                            Details : Eton Pharmaceuticals Canadian rights to ALKINDI® SPRINKLE from Diurnal Group plc. Eton Pharmaceuticals currently commercializes ALKINDI® SPRINKLE in the United States as a replacement therapy for Adrenocortical Insufficiency (AI) in children under 17 y...

                            Brand Name : Alkindi Sprinkle

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 14, 2021

                            Lead Product(s) : Hydrocortisone

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Eton Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Diurnal Group

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Diurnal Group

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydrocortisone

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Diurnal Seeks UK MHRA Marketing Approval for Chronocort to Treat Patients with Rare Condition Congenital Adren...

                            Details : The submission for the MHRA is based on the data from the Company’s Phase 3 study, an open-label safety extension study of Chronocort® and written formal Scientific Advice received in April 2019 confirming the clinical and regulatory pathway for Chron...

                            Brand Name : Chronocort

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 12, 2021

                            Lead Product(s) : Hydrocortisone

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Diurnal Group

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Diurnal Group

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydrocortisone

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : EffRx

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            EffRx Pharma Signs a License Agreement with Diurnal for the Registration and Commercialization of Alkindi®

                            Details : Under the terms of the agreement EffRx has received the exclusive rights to register and commercialize Alkindi® in Switzerland.

                            Brand Name : Alkindi Sprinkle

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 21, 2020

                            Lead Product(s) : Hydrocortisone

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : EffRx

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Diurnal Group

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Diurnal Group

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydrocortisone

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Eton Pharmaceuticals

                            Deal Size : $7.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Eton Pharmaceuticals Announces Acquisition of U.S Marketing Rights to Pediatric Orphan Drug Alkindi® Sprinkle

                            Details : The acquisition advanced Eton’s leadership in pediatric rare diseases products providing a $100 million market opportunity.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : $3.5 million

                            March 27, 2020

                            Lead Product(s) : Hydrocortisone

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Eton Pharmaceuticals

                            Deal Size : $7.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth